Charles Schwab Investment Management Inc. Purchases 40,218 Shares of Certara, Inc. $CERT

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Certara, Inc. by 5.3%, now holding about 797,610 shares valued at approximately $7.90 million.
• Several institutional investors have significantly boosted their positions in Certara, with ArrowMark Colorado Holdings LLC increasing its stake by a remarkable 164.2%.
• Certara reported a quarterly earnings miss, posting $0.07 earnings per share against analysts' expectations of $0.10, despite a year-over-year revenue increase of 12.1%.

Charles Schwab Investment Management Inc. grew its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 5.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 797,610 shares of the company's stock after buying an additional 40,218 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.49% of Certara worth $7,896,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CERT. Wells Fargo & Company MN increased its stake in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Certara during the 4th quarter worth approximately $3,628,000. Mariner LLC lifted its position in Certara by 26.5% during the 4th quarter. Mariner LLC now owns 23,823 shares of the company's stock worth $254,000 after acquiring an additional 4,991 shares in the last quarter. Marshall Wace LLP lifted its position in Certara by 11.3% during the 4th quarter. Marshall Wace LLP now owns 47,855 shares of the company's stock worth $510,000 after acquiring an additional 4,855 shares in the last quarter. Finally, First Trust Advisors LP acquired a new position in shares of Certara in the 4th quarter valued at approximately $140,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Performance

Shares of NASDAQ:CERT traded down $0.03 during trading on Friday, hitting $10.84. 817,541 shares of the stock were exchanged, compared to its average volume of 1,687,319. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of 216.84 and a beta of 1.42. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $15.69. The company's fifty day simple moving average is $10.82 and its 200-day simple moving average is $11.50.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The company had revenue of $104.57 million for the quarter, compared to the consensus estimate of $104.14 million. During the same quarter last year, the business earned $0.07 EPS. Certara's quarterly revenue was up 12.1% compared to the same quarter last year. Sell-side analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Morgan Stanley assumed coverage on Certara in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price target on the stock. KeyCorp decreased their price target on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. UBS Group decreased their price target on Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. JMP Securities restated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Finally, Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $15.14.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.